Iricryn

Bimatoprost, the active ingredient in Iricryn, is a prostaglandin analog presented as an ophthalmic solution for ocular (topical) use. Approved in the European Union, it lowers intra‑ocular pressure to manage open‑angle glaucoma and ocular hypertension in adult patients.

GNH USA supplies Iricryn as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality, regulatory adherence, and reliable logistics for global eye‑care providers. Our distribution network covers Europe, Asia, Africa and the Americas, facilitating timely delivery and support for clinical practice.

Iricryn, a prostaglandin analog, is used to manage conditions that involve elevated intra‑ocular pressure.

- Open‑angle glaucoma: reduces intra‑ocular pressure to slow disease progression. - Ocular hypertension: lowers eye pressure to prevent conversion to glaucoma. - Elevated intra‑ocular pressure: provides pressure reduction in patients at risk of developing glaucoma.

Iricryn may cause a range of ocular reactions, most of which are mild and transient.

Common Side Effects: - Eye redness: mild conjunctival hyperemia. - Eye itching or irritation: transient discomfort after instillation. - Increased eyelash growth: longer, thicker lashes may develop. - Darkening of iris: gradual increase in iris pigmentation.

Serious or Rare Side Effects: - Uveitis: inflammation of the uveal tract requiring medical attention. - Macular edema: swelling of the central retina that can affect vision. - Vision loss: rare but severe decrease in visual acuity. - Severe allergic reaction: swelling, rash, or difficulty breathing.

Before using Iricryn, consider the following safety measures.

- Monitor intra‑ocular pressure: schedule regular measurements to assess therapeutic response. - Assess for ocular infections: avoid use in eyes with active infection or inflammation. - Discontinue contact lens wear: remove lenses before and for at least 15 minutes after instillation. - Pregnancy and lactation: use only if the potential benefit justifies the potential risk to the fetus or infant. - Systemic absorption caution: be vigilant in patients with asthma or known hypersensitivity to prostaglandins. - Store at room temperature: keep in the original container, protect from light and moisture.

Iricryn can interact with other ocular or systemic agents; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Concomitant prostaglandin analogs: additive pressure‑lowering effect may cause excessive IOP reduction. - Preservative‑containing anesthetic drops: increased risk of corneal toxicity. - Systemic carbonic anhydrase inhibitors: may diminish the IOP‑lowering efficacy of Bimatoprost.

Moderate Interactions (Monitor Closely): - Topical non‑steroidal anti‑inflammatory eye drops: may increase ocular irritation. - Topical beta‑blockers: additive IOP‑lowering effect warrants careful monitoring.